FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940831409> ?p ?o ?g. }

• W2940831409 endingPage "93" @default.
• W2940831409 startingPage "87" @default.
• W2940831409 abstract "Background Anti-platelet therapy is commonly used in patients receiving oral anticoagulation and may increase bleeding risk among patients undergoing cardiac implantable electronic device (CIED) surgery. We sought to determine the proportion of anticoagulated patients who are concomitantly receiving anti-platelet therapy, the associated risk of clinically significant hematoma (CSH), and the proportion of patients in whom anti-platelet usage is guideline-indicated. Methods A secondary analysis of the Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL). Patients who were receiving warfarin, had an annual predicted risk of thromboembolism of ≥5% and were scheduled to undergo non-emergent CIED surgery were randomized to continued warfarin versus heparin bridging. In the current analysis, patients were divided into those receiving anti-platelet therapy and those not receiving anti-platelet therapy. The incidence of CSH was compared in both groups. The proportion of patients on potentially inappropriate and potentially interruptible antiplatelet therapy was estimated. Results All 681 patients enrolled in BRUISE CONTROL were included, of whom 280 received and 401 did not receive anti-platelet therapy. Anti-platelet therapy increased the risk of CSH (relative risk, 1.72; 95% confidence interval (CI), 1.09 to 2.72; P = 0.02). Of the 280 patients receiving anti-platelet therapy, 97 (34.6%) had no guideline indication for concomitant anti-platelet therapy and an additional 146 (52.1%) were on anti-platelet therapy that could potentially have been interrupted around CIED surgery. Conclusions Concomitant anti-platelet therapy in patients receiving anticoagulation is associated with a significant risk of CSH. The majority of concomitant anti-platelet therapy is potentially inappropriate or interruptible. Trial registration clinicaltrials.gov Identifier: (NCT00800137)" @default.
• W2940831409 created "2019-05-03" @default.
• W2940831409 creator A5000533995 @default.
• W2940831409 creator A5001640790 @default.
• W2940831409 creator A5009706863 @default.
• W2940831409 creator A5010703194 @default.
• W2940831409 creator A5022557025 @default.
• W2940831409 creator A5030796618 @default.
• W2940831409 creator A5035644440 @default.
• W2940831409 creator A5042249261 @default.
• W2940831409 creator A5044281280 @default.
• W2940831409 creator A5045506197 @default.
• W2940831409 creator A5058534795 @default.
• W2940831409 creator A5059788556 @default.
• W2940831409 creator A5068138290 @default.
• W2940831409 creator A5077545244 @default.
• W2940831409 creator A5077573193 @default.
• W2940831409 creator A5077998702 @default.
• W2940831409 creator A5078114484 @default.
• W2940831409 creator A5081819461 @default.
• W2940831409 creator A5082592297 @default.
• W2940831409 creator A5087143141 @default.
• W2940831409 creator A5088654566 @default.
• W2940831409 creator A5090784624 @default.
• W2940831409 date "2019-08-01" @default.
• W2940831409 modified "2023-10-18" @default.
• W2940831409 title "Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial" @default.
• W2940831409 cites W1508695273 @default.
• W2940831409 cites W1584955229 @default.
• W2940831409 cites W1979363567 @default.
• W2940831409 cites W1990484153 @default.
• W2940831409 cites W2010745807 @default.
• W2940831409 cites W2031080542 @default.
• W2940831409 cites W2042033948 @default.
• W2940831409 cites W2046051565 @default.
• W2940831409 cites W2053823620 @default.
• W2940831409 cites W2066546503 @default.
• W2940831409 cites W2069340802 @default.
• W2940831409 cites W2079964926 @default.
• W2940831409 cites W2089255629 @default.
• W2940831409 cites W2115041325 @default.
• W2940831409 cites W2115054722 @default.
• W2940831409 cites W2116481772 @default.
• W2940831409 cites W2124247204 @default.
• W2940831409 cites W2138247049 @default.
• W2940831409 cites W2145393306 @default.
• W2940831409 cites W2163200991 @default.
• W2940831409 cites W2278387784 @default.
• W2940831409 cites W2298495572 @default.
• W2940831409 cites W2300700903 @default.
• W2940831409 cites W2413457902 @default.
• W2940831409 cites W2521989809 @default.
• W2940831409 cites W2546704212 @default.
• W2940831409 cites W2580840002 @default.
• W2940831409 cites W2596816418 @default.
• W2940831409 cites W2763010902 @default.
• W2940831409 cites W2776894078 @default.
• W2940831409 cites W2886027203 @default.
• W2940831409 cites W2916350381 @default.
• W2940831409 cites W2975859535 @default.
• W2940831409 cites W3004050106 @default.
• W2940831409 cites W4205645630 @default.
• W2940831409 cites W4211129082 @default.
• W2940831409 cites W4243204328 @default.
• W2940831409 doi "https://doi.org/10.1016/j.ijcard.2019.04.066" @default.
• W2940831409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31056413" @default.
• W2940831409 hasPublicationYear "2019" @default.
• W2940831409 type Work @default.
• W2940831409 sameAs 2940831409 @default.
• W2940831409 citedByCount "10" @default.
• W2940831409 countsByYear W29408314092019 @default.
• W2940831409 countsByYear W29408314092020 @default.
• W2940831409 countsByYear W29408314092021 @default.
• W2940831409 countsByYear W29408314092022 @default.
• W2940831409 crossrefType "journal-article" @default.
• W2940831409 hasAuthorship W2940831409A5000533995 @default.
• W2940831409 hasAuthorship W2940831409A5001640790 @default.
• W2940831409 hasAuthorship W2940831409A5009706863 @default.
• W2940831409 hasAuthorship W2940831409A5010703194 @default.
• W2940831409 hasAuthorship W2940831409A5022557025 @default.
• W2940831409 hasAuthorship W2940831409A5030796618 @default.
• W2940831409 hasAuthorship W2940831409A5035644440 @default.
• W2940831409 hasAuthorship W2940831409A5042249261 @default.
• W2940831409 hasAuthorship W2940831409A5044281280 @default.
• W2940831409 hasAuthorship W2940831409A5045506197 @default.
• W2940831409 hasAuthorship W2940831409A5058534795 @default.
• W2940831409 hasAuthorship W2940831409A5059788556 @default.
• W2940831409 hasAuthorship W2940831409A5068138290 @default.
• W2940831409 hasAuthorship W2940831409A5077545244 @default.
• W2940831409 hasAuthorship W2940831409A5077573193 @default.
• W2940831409 hasAuthorship W2940831409A5077998702 @default.
• W2940831409 hasAuthorship W2940831409A5078114484 @default.
• W2940831409 hasAuthorship W2940831409A5081819461 @default.
• W2940831409 hasAuthorship W2940831409A5082592297 @default.
• W2940831409 hasAuthorship W2940831409A5087143141 @default.
• W2940831409 hasAuthorship W2940831409A5088654566 @default.
• W2940831409 hasAuthorship W2940831409A5090784624 @default.
• W2940831409 hasConcept C126322002 @default.

• next